A Korean Post-Marketing Surveillance Study of Dolutegravir Single-Agent Tablets in Patients with HIV-1

BACKGROUND: The integrase strand transfer inhibitor dolutegravir has been indicated in Korea since 2014 for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. This regulatory post-marketing surveillance (PMS) study evaluated the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Sungshin, Cho, Jung-Eun, Lee, Eun-Bin, Kim, Yeon-Sook, Sohn, Jang-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840956/
https://www.ncbi.nlm.nih.gov/pubmed/36596681
http://dx.doi.org/10.3947/ic.2022.0058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840956/
https://www.ncbi.nlm.nih.gov/pubmed/36596681
http://dx.doi.org/10.3947/ic.2022.0058

Ejemplares similares